Ronald Krall to join GSK as head of worldwide development

Published: 18-Feb-2003


GlaxoSmithKline (GSK) has appointment of Dr Ronald Krall as senior vice president, Worldwide Development, Research & Development, effective 19 February. Krall will have global responsibility at GSK for clinical development, medical affairs and regulatory affairs.

'Dr Krall brings to GSK broad scientific and clinical knowledge, international experience, and a strong record in pharmaceutical r&d,' said Tadataka Yamada, chairman, GSK r&d. 'He shares our sense of urgency about creating innovative medicines for patients in need.'

Krall holds a BA in mathematics from Swarthmore College and an MD degree from the University of Pittsburgh and is board-certified in neurology. He has led drug-development programs in numerous therapeutic areas during his two decades in the pharmaceutical industry. Since 1992, he has worked in senior r&d management positions at AstraZeneca and one of its predecessor companies, including roles in which he headed global clinical development. Most recently, he was senior vp, US drug development at AstraZeneca with responsibility for all US clinical and regulatory activities.

You may also like